Drug intelligence / Profile preview

anti-Hla neutralizing antibody

Development stage
Unknown
Lead developer
Aridis Pharmaceuticals
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-Hla neutralizing antibodies (often misspelled as anti-HLA neutralization antibodies) are a class of monoclonal or polyclonal antibodies that target and neutralize the alpha-toxin (alpha-hemolysin, Hla) secreted by *Staphylococcus aureus*. Alpha-toxin is a key virulence factor that forms heptameric pores in host cell membranes (such as red blood cells, platelets, and endothelial cells) by binding to its cellular receptor, ADAM10, leading to cell lysis and tissue damage. By binding to Hla, these neutralizing antibodies prevent pore formation and protect host tissues from toxin-mediated injury. This therapeutic approach is being investigated for the prevention and treatment of *S. aureus* infections, including skin and soft tissue infections (SSTIs) and pneumonia, as an alternative or adjunct to traditional antibiotics.

Other names
anti-HLA neutralization antibodyanti-HLA neutralizing antibodyanti-Hla neutralizing antibodiesanti-alpha-hemolysin neutralizing antibodyanti-alpha-toxin neutralizing antibody
02

Targets

ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)Hla (Staphylococcus aureus alpha toxin)

Beyond the preview

Go deeper on anti-Hla neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-Hla neutralizing antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call